Higher tetanus toxoid immunity 2 years after PsA-TT introduction in Mali

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S578-S585

  Basta, Nicole E ^a,b   Borrow, Ray ^c   Berthe, Abdoulaye ^d   Onwuchekwa, Uma ^d   Dembélé, Awa Traoré Eps ^d   Almond, Rachael ^c   Frankland, Sarah ^c   Patel, Sima ^c   Wood, Daniel ^c   Nascimento, Maria ^e   Manigart, Olivier ^e,f   Trotter, Caroline L ^g   Greenwood, Brian ^e   Sow, Samba O ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d MINISTÈRE DE LA SANTÉ   (Mali)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Medical Research Council Unit   (Gambia)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Africa; conjugate; meningococcal vaccines; seroprevalence; tetanus

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; TETANUS TOXOID; BACTERIUM ANTIBODY; TETANUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNITY; MALE; MALI; MASS IMMUNIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; ADOLESCENT; BLOOD; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MALI; MENINGOCOCCAL VACCINES; TETANUS ANTITOXIN; TETANUS TOXOID; YOUNG ADULT;

EID: 84947571236     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ513     Document Type: Article

References (22)

1. Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013; 9: 2505-23.
2. Maiden MC. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philos Trans R Soc Lond B Biol Sci 2013; 368:20120147.
3. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20.
4. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (MenAfriVac®) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014; 383:40-7.
5. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012; 8:715-24.
6. World Health Organization. Summary of WHO position papers-recommendations for routine immunization. Available at: http://www. who.int/immunization/policy/Immunization-routine-Dable1.pdf?ua=1. Accessed 5 January 2015.
7. Strategic Advisory Group of Experts on Immunization. 2014 assessment report of the Global Vaccine Action Plan. Available at: http://www.who. int/immunization/sage/meetings/2014/october/1-GVAP-Assessment-Report-2014-draft-SAGE-discussion.pdf. Accessed 5 January 2015.
8. Centers for Disease Control and Prevention. Global routine vaccination coverage-2012. MMWR Morb Mortal Wkly Rep 2013; 62: 858-61.
9. World Health Organization. Tetanus vaccine. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations. Wkly Epidemiol Rec 2006; 81:198-208.
10. World Health Organization. Immunization, vaccines, and biologicals. Data, statistics, and graphics. Available at: http://www.who.int/ immunization/monitoring-surveillance/data/en/. Accessed 13 January 2015.
11. World Health Organization. Mali: WHO and UNICEF estimates of immunization coverage: 2013 revision. Available at: http://www.who.int/ immunization/monitoring-surveillance/data/mli.pdf. Accessed 5 January 2015.
12. Owusu-Darko S, Diouf K, NourNM. Elimination ofmaternal and neonatal tetanus: a 21st-century challenge. Rev Obstet Gynecol 2012; 5:e151-7.
13. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151-61.
14. United Nation's Children's Fund. Elimination of maternal and neonatal tetanus. Available at: http://www.unicef.org/health/index-43509.html. Accessed 5 January 2015.
15. World Health Organization Secretariat Annual Report. Global Vaccine Action Plan monitoring, evaluation, and accountabilty. Available at: http://www.who.int/immunization/global-vaccine-Action-plan/GVAP-secretariat-report-2013.pdf?ua=1. Accessed 5 January 2015.
16. Organisation mondiale de la sante. Programme elargi de vaccination. Evaluation de la campagne de vaccination contre la meningite avec le vaccine MenAfriVac 2eme phase, dans les regions de Koulikoro, Segou et le district de Bamako au Mali en 2010. 2011.
17. MenAfriCar Carriage Consortium. Meningococcal carriage in the African meningitis belt. Trop Med Int Health 2013; 18:968-78.
18. Basta NE, Borrow R, Berthe A, et al. Population-level persistence of immunity 2 years after the PsA-DT mass-vaccination campaign in Mali. Clin Infect Dis 2015; 61(suppl 5):S547-53.
19. Pickering JW, Martins TB, Schroder MC, Hill HR. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for quantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae type b. Clin Diagn Lab Immunol 2002; 9:872-6.
20. Staros JV, Wright RW, Swingle DM. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 1986; 156:220-2.
21. Borrow R, Balmer P, Roper M. Module 3: tetanus update 2006. Geneva, Switzerland: World Health Organization, 2007.
22. Borrow R, Tang Y, Yakubu A, Kulkarni PS, LaForce FM. MenAfriVac as an antitetanus vaccine. Clin Infect Dis 2015; 61(suppl 5):S570-7.